Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Consun Pharmaceutical GroupFRA:C1P 78 Shareholder Yield % is 8.31% as of Dec. 2025, which is 34% above its 10-year median of 6.20. GuruFocus rates FRA:C1P with a GF Score™ of 78/100 and a GF Value™ of €0.92 (Significantly Overvalued). The stock has 1 warning sign investors should review. Among 972 Drug Manufacturers companies, Consun Pharmaceutical Group ranks better than 90.23% on this metric.
Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. It is a measure of shareholder return.
As of today, Consun Pharmaceutical Group's Shareholder Yield % was 8.31%.
Consun Pharmaceutical Group (FRA:C1P) Shareholder Yield % Explanation
Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. The term was coined by William W. Priest of Epoch Investment Partners in a paper in 2005 entitled The Case for Shareholder Yield as a Dominant Driver of Future Equity Returns. William Priest indicated that "shareholder yield is a term that we came up with to reflect the various ways dividends can be paid to owners of a business in a publicly-traded company."
Dividend Yield % shows how much a company pays out in dividends each year relative to its stock price, which is most obvious form of shareholder return.
Buyback Yield % is the net repurchase of shares outstanding over the market capital of the company. Shares repurchases also increase shareholder value by returning the money back to shareholders.
Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced.
Consun Pharmaceutical Group Shareholder Yield % Related Terms
Consun Pharmaceutical Group Shareholder Yield % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Consun Pharmaceutical Group Shareholder Yield % Chart
FRA:C1P vs ZTS, UTHR: Shareholder Yield % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Consun Pharmaceutical Group's Shareholder Yield %, along with its competitors' market caps and Shareholder Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Consun Pharmaceutical Group Shareholder Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Consun Pharmaceutical Group's Shareholder Yield % distribution charts can be found below:
* The bar in red indicates where Consun Pharmaceutical Group's Shareholder Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Shareholder Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.
Consun Pharmaceutical Group (FRA:C1P) has a Shareholder Yield % of 8.31% as of Dec. 2025. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on Consun Pharmaceutical Group and its competitors. This is 34% above median its historical median of 6.20. Over the past decade, Consun Pharmaceutical Group's Shareholder Yield % has ranged from 1.97 to 15.64. According to the industry distribution chart, Consun Pharmaceutical Group ranks #95 out of 972 companies in the Drug Manufacturers industry, placing it in the top 9.8%.
Is Consun Pharmaceutical Group's Shareholder Yield % too high?
Consun Pharmaceutical Group's current Shareholder Yield % of 8.31% is 34% above median its 10-year median of 6.20. Over the past 10 years, this metric has ranged from a low of 1.97 to a high of 15.64. The Drug Manufacturers industry median Shareholder Yield % is 0.29. Consun Pharmaceutical Group's value of 8.31% is 2765.5% above this industry median. Based on the distribution chart, Consun Pharmaceutical Group ranks #95 out of 972 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Consun Pharmaceutical Group has a GF Score™ of 78/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Consun Pharmaceutical Group's Shareholder Yield % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Consun Pharmaceutical Group ranks #95 out of 972 companies for Shareholder Yield %. This places Consun Pharmaceutical Group in the top 10% of its industry — outperforming the majority of peers. The industry median Shareholder Yield % is 0.29. Consun Pharmaceutical Group's value of 8.31% is 2765.5% above this benchmark. Historically, Consun Pharmaceutical Group's own Shareholder Yield % has ranged from 1.97 to 15.64 over the past decade. While the company's 10-year median is 6.20 vs. the industry median of 0.29, Consun Pharmaceutical Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shareholder Yield % for a Drug Manufacturers company?
The median Shareholder Yield % among Drug Manufacturers companies is 0.29, based on 972 companies in the industry. Companies in the top quartile (top 25%) have a Shareholder Yield % significantly above this median, while those in the bottom quartile fall well below. However, Shareholder Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Consun Pharmaceutical Group's current Shareholder Yield % of 8.31% is 2765.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shareholder Yield % mean?
A high Shareholder Yield % can signal that a stock is expensive relative to its fundamentals. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on Consun Pharmaceutical Group and its competitors. For the Drug Manufacturers industry, the median Shareholder Yield % is 0.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Consun Pharmaceutical Group's current Shareholder Yield % is 8.31%, which is 34% above median its own 10-year median of 6.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Consun Pharmaceutical Group stock overvalued right now?
Based on GuruFocus' analysis, Consun Pharmaceutical Group (FRA:C1P) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.92, compared to a current price of €1.50 — trading 63% above its estimated fair value. The current Shareholder Yield % is 8.31%, which is 34% above median its 10-year median of 6.20 and 2765.5% above the Drug Manufacturers industry median of 0.29. Consun Pharmaceutical Group's overall GF Score™ is 78/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shareholder Yield % calculated?
Shareholder Yield % is calculated from a company's financial statements. For Consun Pharmaceutical Group (FRA:C1P), the current Shareholder Yield % is 8.31% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Consun Pharmaceutical Group (FRA:C1P) Overvalued in 2026?
Based on GuruFocus' analysis, Consun Pharmaceutical Group stock appears to be overvalued.
The current stock price of €1.50 is trading 63% above its estimated GF Value™ of €0.92.
GuruFocus considers Consun Pharmaceutical Group to be Significantly Overvalued.
Key valuation signals for FRA:C1P:
Shareholder Yield %: 8.31% (34% above median its 10-year median of 6.20)
GF Value™: €0.92 vs. price of €1.50 (63% above fair value)
Industry Position: 2765.5% above the Drug Manufacturers median (#95 of 972)
No single metric tells the full story. See the FRA:C1P stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Consun Pharmaceutical Group Ltd is a biotechnology company with a modern pharmaceutical enterprise that integrates R&D, production, and marketing. The company has two reportable segments: the Consun pharmaceutical segment, which is the key revenue driver, and makes and sells modern Chinese medicines and medical contrast medium, and the Yulin pharmaceutical segment, which manufactures and sells traditional Chinese medicines. Company derives revenue from kidney medicines, contrast mediums, orthopedics medicines, dermatologic medicines, hepatobiliary medicines, medicines for women and children, and others.
78GF Score
Get the complete analysis for FRA:C1P
Shareholder Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:C1P has been successfully added to your 
